Commercial Credit Report for Destiny Pharma PLC

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Destiny Pharma PLC is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Destiny Pharma PLC
Sussex Innovation Centre
Science Park Square, Falmer
Phone: +44 1273704440p:+44 1273704440	BRIGHTON, BN1 9SB United Kingdom	Ticker: DESTDEST


Placed into Administration on 8/21/2024 On 8/21/2024, Destiny Pharma PLC was placed into Administration. Stephen Cork and Mark Smith of Cork Gully LLP were appointed as the joint Administrators.
This company is no longer actively traded on any major stock exchange.

Business Summary

Destiny Pharma plc is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of novel medicines that can prevent life-threatening infections. The Company's drug development pipeline includes two late stage assets, NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.difficile infection (CDI) recurrence, which is the principal cause of hospital acquired infection in the United States, and XF-73 nasal gel, a proprietary drug targeting the prevention of postsurgical staphylococcal hospital infections including methicillin-resistant Staphylococcus aureus (MRSA), and has the potential to reduce hospitalization stay, accelerate recovery and rehabilitation and improve quality of life for patients undergoing vital surgeries. The Company’s earlier stage pipeline is focused on other indications including two, separate dermal programs incorporating its XF platform.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
-	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2023	12/31/2023	Yes	-	-	-	-

Industries

SIC Code	Description
8731	Commercial physical and biological research

Officers and Directors

Title	Name	Age	Title Date	Start Date
Non-Executive Chairman of the Board	Anthony Nigel R.Rudd	77	7/25/2023	9/1/2011
Non-Executive Chairman	Sir NigelRudd
Chief Executive Officer, Executive Director	Christopher J.Tovey	59	9/1/2023	9/1/2023
11 additional Officers and Directors records available in full report.

General Information

Number of Employees:	19	(As of 12/31/2023)
Outstanding Shares:	95,770,611	(As of 6/25/2024)
Stock Exchange:	LON
Fax Number:	+44 1273704414

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN